• Ubie

  Participated · Series C · Dec 2022

  Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.

No current team members are available.